# A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection

> **NCT00717470** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 1252 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Prograf®
- **DRUG:** Advagraf®
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Simulect
- **DRUG:** methylprednisolone / prednisone

## Key facts

- **NCT ID:** NCT00717470
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-14
- **Primary completion:** 2010-03-02
- **Final completion:** 2010-03-02
- **Target enrollment:** 1252 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00717470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00717470, "A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00717470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*